Regression of central giant cell granuloma by a combination of imatinib and interferon: a case report.

Abstract

Central giant cell granuloma is a benign lesion of the jaws which is sometimes aggressive locally. The most common treatment is curettage,which has a high recurrence rate, particularly in more aggressive lesions. Other treatments such as interferon (IFN) and calcitonin have been described. We report a patient with Stickler syndrome and an aggressive central giant cell granuloma in the mandible. Initial treatment with calcitonin was not successful. A combination of IFN and imatinib, given for 9 months, initiated regression of the lesion that continued after treatment had ceased.

• Authors: Jan de Lange, Rick R van Rijn, Henk van den Berg, Hans P van den Akker
• Journal: The British journal of oral & maxillofacial surgery (Br J Oral Maxillofac Surg) Vol. 47 Issue 1 Pg. 59-61 (Jan 2009) ISSN: 1532-1940 [Electronic] Scotland
• PMID: 18656288 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Benzamides
• Drug Combinations
• Interferon alpha-2
• Interferon-alpha
• Piperazines
• Pyrimidines
• Recombinant Proteins
• Polyethylene Glycols
• Imatinib Mesylate
• Calcitonin
• peginterferon alfa-2a

Topics

• Adolescent
• Antineoplastic Agents (therapeutic use)
• Benzamides
• Calcitonin (therapeutic use)
• Collagen Diseases (chemically induced)
• Drug Combinations
• Female
• Granuloma, Giant Cell (complications, drug therapy)
• Humans
• Imatinib Mesylate
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Mandibular Diseases (complications, drug therapy)
• Piperazines (therapeutic use)
• Polyethylene Glycols (therapeutic use)
• Pyrimidines (therapeutic use)
• Recombinant Proteins
• Remission Induction
• Syndrome